ValiRx - Half-year Report
VAL Tue, 27 Sep 2016, 02:50pm BST
Oliver de Giorgio-Miller, Non-Executive Chairman, comments on the significant progress that ValiRx is making in its clinical trials. ValiRx is pleased with the momentum created in the first half of 2016 as they move towards exciting clinical developmental milestones and potential value inflection points as far as VAL201, 301 and 401 therapeutic compounds are concerned. The funding recently secured provides a cash runway towards reaching these.
Oliver de Giorgio-Miller
Non-Executive Chairman
Dr Cathy Tralau-Stewart, Chief Scientific Officer
Thu, 21 Mar 2024, 7:05am GMT
Dr Cathy Tralau-Stewart, Chief Scientific Officer
Mon, 12 Feb 2024, 3:00pm GMT
Suzanne Dilly, Chief Executive Officer
Tue, 5 Dec 2023, 2:00pm GMT
Suzanne Dilly, Chief Executive Officer
Thu, 28 Sep 2023, 7:00am BST
Suzanne Dilly, Chief Executive Officer
Wed, 14 Jun 2023, 3:00pm BST
Suzanne Dilly, Chief Executive Officer
Tue, 31 Jan 2023, 2:28pm GMT
Suzanne Dilly, Chief Executive Officer
Thu, 26 Jan 2023, 1:32pm GMT
Professor Martin Ulmschneider, Head of Department of Chemistry - Kings...
Fri, 28 Oct 2022, 4:45pm BST
Suzanne Dilly, Chief Executive Officer
Thu, 29 Sep 2022, 4:27pm BST
Suzanne Dilly, Chief Executive Officer
Thu, 14 Jul 2022, 1:30pm BST
Suzanne Dilly, Chief Executive Officer
Thu, 30 Jun 2022, 11:00am BST
ValiRx - Board Members, ValiRx PLC
Wed, 6 Apr 2022, 5:00pm BST
Suzanne Dilly, Chief Executive Officer
Wed, 23 Mar 2022, 12:56pm GMT
Suzanne Dilly, Chief Executive Officer
Wed, 5 Jan 2022, 12:00pm GMT
Suzanne Dilly, Chief Executive Officer
Mon, 20 Dec 2021, 12:20pm GMT
Suzanne Dilly, Chief Executive Officer
Fri, 26 Nov 2021, 4:48pm GMT
Suzanne Dilly, Chief Executive Officer
Tue, 2 Nov 2021, 5:00pm GMT
Suzanne Dilly, Chief Executive Officer
Fri, 28 May 2021, 12:30pm BST
